海思科 (002653)
Haisco Pharmaceutical Group Co.,Ltd
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 111991.80
- Circulating A-Shares(W): 48323.82
- Earnings Per Share(RMB): 0.2637
- Net Assets Per Share(RMB): 3.7745
- Operating Revenue(W RMB): 330013.60
- Total Profit(W RMB): 33771.42
- Net Profit Attributable to Parent(W RMB): 29530.07
- Net Profit Growth Rate(%): -22.66
- Weighted Return on Equity(%): 7.0800
- Operating Cash Flow Per Share(RMB): 0.3480
- Undistributed Profit Per Share(RMB): 1.5542
- Capital Reserve Per Share(RMB): 0.8921
2. Main Business
The main business covers:
- New drug research and development
- Production and manufacturing
- Promotion and marketing business
3. Company Basic Information
- Company Name: Haisco Pharmaceutical Group Co., Ltd.
- Listing Date: 2012-01-17
- Industry: Pharmaceutical Manufacturing
- Address: No. 17 Sanxiang Avenue, Zedang Town, Shannan City, Tibet Autonomous Region
- Website: www.haisco.com
- Company Profile: The company's predecessor was Tibet Kangxin Pharmaceutical Co., Ltd., established on August 26, 2005; later, through a resolution of the shareholders' meeting on October 16, 2009, it was renamed Tibet Haisco Pharmaceutical Group Co., Ltd. on March 24, 2010. On August 3, 2010, the shareholders' meeting of Haisco Co., Ltd. passed a resolution to convert Haisco Co., Ltd. into Tibet Haisco Pharmaceutical Group Co., Ltd. with all shareholders as promoters, based on the audited net assets of 246,842,945.13 RMB as of June 30, 2010, converted into 190,000,000 shares (par value 1.00 RMB per share) at a ratio of 1:0.76972. The registered capital was 190 million RMB, and the remaining amount after conversion was included in "Capital Reserve - Capital Premium." All assets, liabilities, business, and personnel of Haisco Co., Ltd. were assumed by the newly established joint-stock company. Zhongrui Yuehua verified the promoters' capital contribution and issued the "Zhongrui Yuehua Yan Zi [2010] No. 198" "Capital Verification Report" on August 3, 2010, confirming that the company's registered capital had been fully paid. On August 23, 2010, the company completed the industrial and commercial registration at the Shannan District Administration for Industry and Commerce and obtained the "Business License of Enterprise Legal Person" with registration number 5422002000081.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | China Europe Medical Health Hybrid Securities Investment Fund A Class | Fund | 2139.75 | 4.44 |
| 2 | Hong Kong Securities Clearing Company Limited | Northbound Capital | 1806.01 | 3.75 |
| 3 | ICBC Credit Suisse Frontier Medical Equity Securities Investment Fund A Class | Fund | 1560.01 | 3.24 |
| 4 | ChinaAMC Innovation Pharmaceutical Theme Hybrid Securities Investment Fund A Class | Fund | 1305.57 | 2.71 |
| 5 | Fullgoal Precision Medical Flexible Allocation Hybrid Securities Investment Fund A Class | Fund | 806.97 | 1.68 |
| 6 | ChinaAMC Medical Service Flexible Allocation Hybrid Securities Investment Fund A Class | Fund | 587.17 | 1.22 |
| 7 | Fullgoal Pharmaceutical Innovation Equity Securities Investment Fund A Class | Fund | 550.09 | 1.14 |
| 8 | E Fund Health Care Industry Hybrid Securities Investment Fund A Class | Fund | 468.80 | 0.97 |
| 9 | ChinaAMC Daxin Flexible Allocation Hybrid Securities Investment Fund A Class | Fund | 409.24 | 0.85 |
| 10 | ChinaAMC Medical Active Growth One-Year Holding Hybrid Securities Investment Fund A Class | Fund | 292.87 | 0.61 |
5. Concept Sectors
- Vitamins
- Generic Drugs
- Innovative Drugs
- Margin Trading & Securities Lending
- Financial Participation
- Heavy Fund Holdings
- MSCI Constituent
- Zhongchuang 100
- Small and Medium 100
- Shenzhen 300
- Consumption 100
- Small and Medium 300
- Shenzhen Innovation
- Innovation 100
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information